Arbutus Biopharma (ABUS) Total Current Liabilities (2016 - 2025)
Historic Total Current Liabilities for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $5.2 million.
- Arbutus Biopharma's Total Current Liabilities fell 7260.48% to $5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year decrease of 7260.48%. This contributed to the annual value of $15.6 million for FY2024, which is 3054.65% down from last year.
- Arbutus Biopharma's Total Current Liabilities amounted to $5.2 million in Q3 2025, which was down 7260.48% from $5.0 million recorded in Q2 2025.
- Over the past 5 years, Arbutus Biopharma's Total Current Liabilities peaked at $32.9 million during Q4 2022, and registered a low of $5.0 million during Q2 2025.
- Its 5-year average for Total Current Liabilities is $19.0 million, with a median of $20.3 million in 2024.
- In the last 5 years, Arbutus Biopharma's Total Current Liabilities soared by 38422.23% in 2022 and then plummeted by 7777.38% in 2025.
- Arbutus Biopharma's Total Current Liabilities (Quarter) stood at $11.2 million in 2021, then soared by 192.82% to $32.9 million in 2022, then plummeted by 31.56% to $22.5 million in 2023, then crashed by 30.55% to $15.6 million in 2024, then crashed by 66.81% to $5.2 million in 2025.
- Its Total Current Liabilities was $5.2 million in Q3 2025, compared to $5.0 million in Q2 2025 and $19.4 million in Q1 2025.